On July 23, 2019, Unitaid and the KNCV Tuberculosis Foundation signed a US$13.9 million grant agreement to enhance the existing evidence base, drive scaled deployment, and create market access plans and tools for digital adherence technologies to enhance TB medication adherence. This large grant builds seamlessly on the work led by the Bill & Melinda Gates Foundation and TB REACH. The work will be conducted by the ASCENT Consortium, led by KNCV and also including The Aurum Institute, London School of Hygiene & Tropical Medicine (Katherine Fielding), and PATH (Lisa Smith). In addition, the work will leverage technologies that we’ve been working with and supporting for several years now — specifically Wisepill’s evriMED device, 99DOTS , and the integrating adherence platform developed and scaled by Everwell Health.
In addition to our multi-year engagement with Wisepill, 99DOTS, and Everwell Health, we were fortunate to advise Unitaid in connection with their review of the ASCENT proposal. We thank Unitaid (Janet Ginnard, Cherise Scott, Yamuna Mundade, and Essien Ukunna) for that opportunity!
Finally, we congratulate the ASCENT team — KNCV (Kitty van Weezenbeek, Job van Rest, and Kristian van Kalmthout), The Aurum Institute (Gavin Churchyard, Salome Charalambous), London School of Hygiene & Tropical Medicine (Katherine Fielding), PATH (Lisa Smith), and Everwell Health (Bill Thies, Andrew Cross, and Nakull Gupta) — for their hard work in securing this major grant and for their willingness to so significantly advance the efforts to bring adherence support to self-administering TB patients.